DEFA14A: Avalo Therapeutics Acquires AlmataBio in Merger Deal, Secures $115.6 Million Private Placement

Avalo Therapeutics has acquired AlmataBio through a merger and secured a $115.6 million private placement to fund the acquisition and advance its clinical programs.

Summary

• Avalo Therapeutics entered into a merger agreement with AlmataBio on March 27, 2024, resulting in AlmataBio becoming a wholly-owned subsidiary of Avalo.
• Avalo issued 171,605 shares of common stock and 2,412 shares of Series C Preferred Stock, valued at approximately $15 million, to Almata stockholders as consideration for the merger.
• Avalo is obligated to make milestone payments totaling $27.5 million to Almata stockholders upon achieving certain clinical milestones.
• Concurrently with the merger, Avalo entered into a securities purchase agreement for a private placement of $115.6 million.
• The private placement involves the issuance of Series C Preferred Stock and warrants to purchase common stock.
• Net proceeds from the private placement, estimated at $105 million after fees and expenses, will be used for milestone payments to Almata stockholders and general corporate purposes.
• Jonathan Goldman was appointed to Avalo's Board of Directors upon closing of the merger.
• Aaron Kantoff and Samantha Truex were appointed to the Board of Directors effective March 28, 2024.
• The company filed Certificates of Designation for Series C, D, and E Preferred Stock.
• Avalo is required to seek stockholder approval for the conversion of Series C Preferred Stock and the exercise of warrants.
• Avalo is obligated to file a proxy statement with the SEC for a stockholder meeting to seek the Required Stockholder Approval not later than 75 days after March 27, 2024.
• Avalo will file a registration statement for resale of shares of Common Stock underlying the Shares and Warrants, Shares, Warrants and shares of Series C Preferred Stock issued pursuant to the Merger Agreement within 75 days of March 28, 2024, and have such registration statement declared effective with 135 days of March 28, 2024.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a strategic acquisition and a significant capital raise. However, there are also risks and uncertainties associated with the transactions, such as the need for stockholder approval and potential dilution.

Positives

• Avalo's acquisition of AlmataBio expands its pipeline and therapeutic focus.
• The $115.6 million private placement provides Avalo with significant capital to fund its operations and clinical programs.
• The addition of Jonathan Goldman, Aaron Kantoff and Samantha Truex to the Board of Directors brings additional expertise and perspectives to the company.
• The milestone payments are tied to clinical progress, aligning the interests of Avalo and Almata stockholders.
• The company will file a registration statement for resale of shares of Common Stock underlying the Shares and Warrants, Shares, Warrants and shares of Series C Preferred Stock issued pursuant to the Merger Agreement within 75 days of March 28, 2024, and have such registration statement declared effective with 135 days of March 28, 2024.

Negatives

• The issuance of new shares dilutes existing stockholders.
• The requirement for stockholder approval for the conversion of Series C Preferred Stock and exercise of warrants introduces uncertainty.
• The company is prohibited from consummating a subsequent equity or equity-linked financing until the earlier of (i) the first anniversary of the Private Placement without the consent of the lead investors in the Private Placement or (ii) the date the Derivative Shares (as defined therein) are freely tradeable without any restriction or limitation, whether under Rule 144 of the Securities Act or an effective registration statement.

Risks

• Failure to obtain stockholder approval for the conversion of Series C Preferred Stock and exercise of warrants could negatively impact the company's financial flexibility.
• Clinical trial milestones may not be achieved, resulting in a failure to make milestone payments to Almata stockholders.
• The company may not be able to successfully integrate AlmataBio's operations and technology.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company may face competition from other companies in the biotechnology industry.
• If the registration statement is not declared effective by that date, the Company will make pro rata payments to each Purchaser in the amount equal to 1.0% of the aggregate amount invested by each Purchaser for the Shares and Warrants then held by such Purchaser upon such date of failure and the same amount monthly thereafter until the registration statement is declared effective.

Future Outlook

The company anticipates using the proceeds from the private placement to fund milestone payments to Almata stockholders and for general corporate purposes. The company expects to file a proxy statement with the SEC relating to the Required Stockholder Approvals. The company expects to file financial statements and pro forma financial information related to the Merger within 71 days.

Industry Context

The acquisition reflects a trend in the biotechnology industry of companies seeking to expand their pipelines through strategic mergers and acquisitions. The private placement demonstrates investor confidence in Avalo's strategy and potential.

Comparison to Industry Standards

• Comparable companies in the biotechnology industry, such as XOMA Corporation and Catalyst Biosciences, have also pursued acquisitions and private placements to advance their clinical programs.
• The terms of the merger agreement and securities purchase agreement appear to be consistent with industry standards for similar transactions.
• The milestone payments are structured to align with clinical development milestones, which is a common practice in the biotechnology industry.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Employees may be affected by the integration of AlmataBio's operations.
• Customers may benefit from the expanded pipeline and therapeutic focus.
• Suppliers and creditors may be affected by the company's financial performance and strategic direction.

Next Steps

• Seek stockholder approval for the conversion of Series C Preferred Stock and exercise of warrants.
• File financial statements and pro forma financial information related to the Merger.
• Advance clinical development programs.
• File a registration statement for resale of shares of Common Stock underlying the Shares and Warrants, Shares, Warrants and shares of Series C Preferred Stock issued pursuant to the Merger Agreement within 75 days of March 28, 2024, and have such registration statement declared effective with 135 days of March 28, 2024.

Key Dates

Keywords

Merger, Acquisition, Private Placement, Preferred Stock, Warrants, Clinical Trials, Avalo Therapeutics, AlmataBio, Stockholder Approval, Board of Directors